Stockscreener 앱 받기
1.78
2.73%
-0.05
시간 외 거래:
1.78
전일 마감가:
$1.83
열려 있는:
$1.86
하루 거래량:
63,506
Relative Volume:
0.28
시가총액:
$11.94M
수익:
$2.35M
순이익/손실:
$-2.56M
주가수익비율:
-3.9723
EPS:
-0.4481
순현금흐름:
-
1주 성능:
-1.66%
1개월 성능:
+4.71%
6개월 성능:
-6.32%
1년 성능:
-35.74%
1일 변동 폭
$1.75
$1.88
1주일 범위
$1.62
$1.93
52주 변동 폭
$1.50
$2.87
이뮤론 Stock (IMRN) Company Profile
IMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.78 | 10.77M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
이뮤론 주식(IMRN)의 최신 뉴스
Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream - GlobeNewswire Inc.
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
Immuron Crushes Sales Forecast: North America Soars 76%, Global Revenue Breaks Records at $7.3M - Stock Titan
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - Markets Insider
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
Immuron LimitedADR Shares Close the Week 61.5% HigherWeekly Wrap - Nasdaq
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
IMC Stock Price and Chart — ASX:IMC - TradingView
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):